Prévisions
L'objectif de cours moyen des analystes est de 159,79 € (+44,42 %). La médiane est de 157,66 € (+42,50 %).
| Acheter |
26 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Protagonist Therapeutics after approvals: over $1 billion cash, $300 million buyback and broad oral pipeline
Protagonist Therapeutics sees its peptide platform validated by the approvals of Icotrokinra and MIMRYLO/Rusfertide and reports a pro-forma cash balance of over $1 billion following a $275 million milestone payment. Management announced a $300 million share repurchase program but emphasized that research and development remain the highest priority. The company is advancing several oral programs (IL‑23/IL‑17/IL‑4, obesity triple agonist) and is selectively seeking partnerships for late-stage development and commercialization. » Plus sur de.investing.com
Protagonist Therapeutics announces $300 million share buyback and plans to use licensing revenue to fund pipeline
At the Citigroup Biopharma Summit, Protagonist Therapeutics highlighted its shift to a commercial phase after two approvals and reported strong launch data for ICOTYDE and positive data for MIMRYLO (Rusfertide). The company plans a $300 million share repurchase program and intends to use future licensing income to finance R&D and enhance shareholder returns. The pipeline focuses on oral peptide therapeutics in immunology, obesity and rare diseases, with Protagonist seeking early partnerships and aiming to advance programs to proof-of-concept. Near-term success and valuation depend on sustained sales of the approved products, progress of the oral candidates and favourable partnerships. » Plus sur de.investing.com
Protagonist Therapeutics approves $300 million share buyback program
The board of directors of Protagonist Therapeutics has approved a share buyback program of up to $300 million, to be funded from cash on hand, cash equivalents, marketable securities and license and collaboration payments. As of June 30, 2026, the company had $849.5 million in cash; additional payments from Takeda totaling $275 million are expected in Q4 2026. The timing and amount of repurchases will depend on market conditions, the share price and license and milestone payments; the program does not obligate the company to buy any specific number of shares. Protagonist generates revenue from royalties under partnerships for MIMRYLO (Rusfertide) with Takeda and ICOTYDE (Icotrokinra) with Johnson & Johnson. » Plus sur de.investing.com
Protagonist Therapeutics receives $275M after MIMRYLO FDA approval, opts for royalties
FDA approval of MIMRYLO (rusfertide) triggered $275 million in payments to Protagonist Therapeutics (a $200M opt-out fee plus a $75M approval milestone). Under the April opt-out, Protagonist agreed to tiered royalties of 14%–29% on worldwide net sales and remains eligible for up to $875 million of additional milestones, while Takeda assumes global development and commercialization. The Phase 3 VERIFY trial showed 76.9% response with MIMRYLO plus standard care versus 32.9% for placebo, but Protagonist relinquishes pricing and launch control and relies on Takeda for market access. The royalty deal provides non-dilutive capital and lower execution risk but limits upside compared with a retained profit share and depends on broad payer and physician adoption. » Plus sur finance.yahoo.com
Protagonist Therapeutics receives $275 million from FDA approval of MIMRYLO (Rusfertide)
The FDA has approved MIMRYLO (Rusfertide) for treatment of erythrocytosis in adults with polycythemia vera, allowing Takeda to commercialize the drug and triggering immediate payments of $275 million to Protagonist (a $200 million opt‑out plus a $75 million approval milestone). Protagonist can also receive up to $875 million in additional milestones and tiered royalties of 14–29% on worldwide net sales. Approval was based on the phase 3 VERIFY study, in which 76.9% of patients treated with MIMRYLO achieved a clinical response versus 32.9% in the placebo group. The most common adverse events were injection‑site reactions (56%) and anemia (16%); treatment is administered weekly by subcutaneous injection. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursEn 2023, Protagonist Therapeutics a déjà versé 180,12 € de dividendes. Le dernier versement a eu lieu en avril 2023.
Données financières
Au dernier trimestre, Protagonist Therapeutics a réalisé un chiffre d'affaires de 242,26 M € et un bénéfice net de 194,24 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 242,26 M | 5 933,59 % |
| Bénéfice brut | 241,29 M | 5 909,40 % |
| Bénéfice net | 194,24 M | 679,44 % |
| EBITDA | 200,03 M | 702,23 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 7,22 Md € |
Nombre d'actions | 65,27 M |
Plus haut/bas sur 52 semaines | 146,55 € - 70,17 € |
| Dividendes | Non |
Bêta | 1,79 |
Ratio P/E | 23,54 |
Ratio PEG | -0,01 |
Ratio P/B | 7,43 |
Ratio P/S | 14,36 |
Profil de l'entreprise
Protagonist Therapeutics, Inc., une société de biopharmaceutique, découvre et développe des médicaments thérapeutiques à base de peptides destinés à traiter les maladies de l'hématologie et les troubles sanguins, ainsi que les maladies inflammatoires et immunomodulatrices. Elle développe le rusfertide (PTG-300), un mimétique injectable de l'hepcidine actuellement en phase II d'essais cliniques pour le traitement des patients atteints de polyglobulie de Vaquez et d'hémochromatose héréditaire, ainsi que pour le traitement d'autres troubles sanguins ; le PN-943, un peptide antagoniste oral et spécifique de l'intégrine alpha-4-bêta-7, actuellement en phase II d'essais cliniques pour le traitement de la maladie inflammatoire chronique de l'intestin (MICI) ; et le PN-235, un antagoniste spécifique du récepteur de l'interleukine-23 à administration orale, destiné au traitement des MICI et d'indications autres que les MICI. La société a conclu un accord de licence et de collaboration avec Janssen Biotech, Inc. Protagonist Therapeutics, Inc. a été constituée en 2006 et son siège social se situe à Newark, en Californie.
| Nom | Protagonist Therapeutics |
| PDG | Dinesh V. Patel |
| Siège social | Newark,
ca États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 11/08/2016 |
| Employés | 141 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | PTGX |